Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

Vice President and Chief Medical Officer at Ironwood.

"These novel findings provide valuable insight into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D., Senior Vice President, R&D and Chief Scientific Officer at Ironwood.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition-throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion ann
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
(Date:5/4/2015)... N.J. , May 4, 2015  Oncobiologics, ... commercializing monoclonal antibody (mAb) biosimilars, has completed the ... at its headquarters in Cranbury, New ... Cranbury facility is designed to utilize ... manufacturing at commercial scale.  Through the use of ...
(Date:5/4/2015)... N.Y. , May 4, 2015  Clinical ... Englert , PharmD, has completed preliminary analysis of ... and Schizophrenia. Resources from Clinical Support Services, Inc. ... Reviews (CMR) with patients currently taking psychiatric medications ... The research found that 93% of patients experienced ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, ... and incorrect application of the efficacy assessment protocol. With this ... dyskinesia symptoms at end of two weeks of active treatment ...
... treatment may target hunger at its source, another uses ... stomach and suppress hunger and a third explores the ... Initial results from all these studies were reported at ... in San Francisco, Calif. (Logo: ...
Cached Medicine Technology:Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 2Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 4Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 5Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 6Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 7No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 2No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 3No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 4No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 5No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 6
(Date:5/4/2015)... (PRWEB) May 04, 2015 Takeda Pharmaceuticals ... billion to settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ... increases the risk that a patient will develop bladder ... 28th, if 95% of those eligible for the Actos ... 9,000 bladder cancer cases currently pending in courts around ...
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 ... insurance programs, announces the expansion of coverage for its ... a leading provider of industry-tailored insurance and proactive risk ... & Company, we are dedicated to providing our customers ... meet their many evolving needs. We are excited to ...
(Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
(Date:5/4/2015)... 04, 2015 TROY Healthcare Solutions is ... Atlantic Regional User Group (RUG) Conference in Baltimore, MD ... Atlantic Regional User Group provides an opportunity for clients ... the exhibitor gallery. , In addition to sponsoring the ... Cerner North Atlantic RUG Conference. Attendees can stop by ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The American ... critical state policy reports which identify gaps in coverage ... “After ATA issued the State Telemedicine Gaps Reports last ... how their laws and regulations impact healthcare delivery in ... a result of state actions across the nation, ATA ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3
... The American Academy of Cosmetic Surgery (AACS) 2006 Consumer Perspective ... US citizens have had cosmetic surgery//, a great number are ... ,Jeff Knezovich, executive vice president of the American Academy ... lot since the 1970s when such surgery was rarely mentioned. ...
... 200 children were taken ill after eating lunch at their ... were admitted to a hospital and are reportedly in a ... Dianshi Town High School began reporting symptoms of headache, stomach ... Monday and were immediately hopitalised. ,The food samples ...
... Health and Family Welfare Minister Anbumani Ramadoss today officially ... The highly contagious disease was prevalent among tribals living ... Last year it was leprosy and this year it ... that India had moved closer to completely eliminating yaws ...
... Children are being exposed to the risk of liver damage ... lead and cadmium found in plastic and other soft toys ... ,"Dangerous levels of lead and cadmium have been found ... the markets," said Toxics Link, an environmental non-governmental organisation, in ...
... that caused by hay fever and other allergies, have ... without allergies, according to a report in the September ... issue on sleep. ,Allergic rhinitis, which occurs ... nasal passages, affects about 20 to 50 percent of ...
... bottles of Similac Infant Formula were off the shelf, after ... following a suspected flaw in the bottle. No repercussions after ... the company has decided to recall the product in order ... C content in the bottle. ,Given ...
Cached Medicine News:Health News:Dangers Lurking in Soft, Cuddly Toys 2Health News:Allergic Rhinitis Associated with Impaired Sleep Quality 2
... has a complete offering of cardiology catheters. ... these catheters are designed with excellent torque, ... and better push-ability, and large inner lumens ... 5, 6 and 7 French sizes with ...
Used to negotiate tortuous vessels....
Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
Used to negotiate tortuous vessels....
Medicine Products: